Evotec (OTCMKTS:EVTCY) versus Acerus Pharmaceuticals (OTCMKTS:ASPCF) Critical Contrast

Profitability

This table compares Acerus Pharmaceuticals and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%
Evotec	20.85%	16.02%	7.81%

Valuation and Earnings

This table compares Acerus Pharmaceuticals and Evotec”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06
Evotec	$572.16 million	2.03	$7.14 million	$0.41	8.59

Evotec has higher revenue and earnings than Acerus Pharmaceuticals. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Acerus Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Evotec has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Summary

Evotec beats Acerus Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

About Evotec

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.